We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Enzymatic Blood Test Could Detect Prediabetes

By LabMedica International staff writers
Posted on 20 Jul 2010
A pilot study reports that O-linked beta-N-acetylglucosamine (O-GlcNAc), an easy-to-detect enzyme in erythrocytes is up to two to three times higher in people with diabetes and pre-diabetes than in those with no disease.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) studied blood samples from volunteers with no diabetes (36 samples), prediabetes (13 samples), and diabetes (53 samples), according to traditional tests that require patient fasting. More...
Erythrocyte proteins were then extracted from the samples, and the hemoglobins were depleted. Then, global O-GlcNAcylation (O-GlcNAc) of the proteins was confirmed by Western blotting using an O-GlcNAc-specific antibody. Relative O-GlcNAc transferase (OGT) and O-GlcNAcase--an enzyme that removes O-GlcNAc in red blood cells--protein amounts were similarly determined. The relative expression of O-GlcNAcase was then compared with the measured level of A1C.

The results showed that erythrocyte proteins are highly O-GlcNAcylated, and O-GlcNAcase expression is significantly increased in erythrocytes from both individuals with prediabetes and diabetes, compared with normal control subjects. However, unlike O-GlcNAcase, protein levels of OGT did not show significant changes. The researchers therefore suggest that the upregulation of O-GlcNAcase might be an adaptive response to hyperglycemia-induced increases in O-GlcNAcylation, which are likely deleterious to erythrocyte functions. The study was published in the July 2010 issue of Diabetes.

"This is an example of how basic research is directly affecting a serious disease,” said Gerald Hart, Ph.D., director of biological chemistry at the JHU School of Medicine. "The question was whether the elevation happened in the earliest stages of diabetes and therefore might have value as a diagnostic tool. Only a much larger clinical trial will determine if, by measuring O-GlcNAcase, we can accurately diagnose prediabetes.”

O-GlcNAc plays an important role in the development of insulin resistance and glucose toxicity, since it modifies many of the cell's proteins to control their functions in response to nutrients (such as glucose and lipids) and stress. O-GlcNAcylation is regulated by OGT, which attaches O-GlcNAc to serine and/or threonine residues of proteins, and by O-GlcNAcase, which removes O-GlcNAc. When the extent of O-GlcNAc attached to proteins becomes too high, as occurs in diabetes, it is harmful to the cell.

Related Links:

Johns Hopkins University




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.